{
  "docId": "019de076-2049-75e8-9528-894c783c20b2",
  "docSlug": "1f0c6538bd85906c2fdac9c48c149895",
  "documentTitle": "argenx SE | Investor Presentation Deck | 25 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 25,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights the two different delivery methods (IV vs Subcutaneous) for the same underlying treatment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2049-75e8-9528-894c783c20b2/5",
  "deckHref": "/decks/019de076-2049-75e8-9528-894c783c20b2",
  "deckJsonHref": "/decks/019de076-2049-75e8-9528-894c783c20b2.json",
  "deckAnchorHref": "/decks/019de076-2049-75e8-9528-894c783c20b2#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.3,
        "y": 0.25
      },
      "kind": "callout",
      "text": "NOW TWO FDA-APPROVED PRODUCTS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f27292f4-1524-40fe-af54-6fd510301814",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "disclaimer",
      "text": "VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b22edb73-e5ff-44b1-a85a-c9f1aaf0699e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.55,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25abc8e5-4c62-4db9-9227-211c02d6c5cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3552d51f-b71d-4939-b167-6c4e239851b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.25,
        "y": 0.05
      },
      "kind": "title",
      "text": "VYVGART for Generalized Myasthenia Gravis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef70a794-db28-4f1a-b2e8-87b8e54b5a85",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "e24cb9a1-4692-46b2-bf33-93b7dc7d3cae",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The presentation identifies the complex treatment landscape and unmet needs in severe autoimmunity.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7f999996-4b0e-4880-900f-cb6c5576ffbb",
      "evidence": "The presentation implies the cost of inaction by highlighting the limitations of current treatments.",
      "position": 0,
      "objective": "What are the consequences of not addressing the unmet needs in severe autoimmunity?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}